High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain

Journal of Clinical Microbiology

Volumn 48, Issue 10, 2010, Pages 3703-3707

  Agudo, Sonia ^a   Pérez Pérez, Guillermo ^b   Alarcón, Teresa ^a   López Brea, Manuel ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; DNA; RIBOSOME RNA;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; EPSILOMETER TEST; FEMALE; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOST RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOSAICISM; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; RISK FACTOR; SPAIN;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; POINT MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; RISK FACTORS; RNA, BACTERIAL; RNA, RIBOSOMAL, 23S; SEQUENCE ANALYSIS, DNA; SPAIN; YOUNG ADULT;

HELICOBACTER PYLORI;

EID: 77957798536     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00144-10     Document Type: Article

References (38)

1. Agudo, S., T. Alarcón, L. Cibrelus, P. Urruzuno, M. Martínez, and M. López-Brea. 2009. High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children. Rev. Esp. Quimioter. 22:88-92.
2. Ahmad, N., W. R. Zakaria, S. A. Abdullah, and R. Mohamed. 2009. Characterization of clarithromycin resistance in Malaysian isolates of Helicobacter pylori. World J. Gastroenterol. 15:3161-3165.
3. Alarcón, T., D. Domingo, M. J. Martinez, and M. López-Brea. 1999. cagA gene and vacA alleles in Spanish Helicobacter pylori clinical isolates from patients of different ages. FEMS Immunol. Med. Microbiol. 24:215-219.
4. Á lvarez, A., J. Moncayo, J. Santacruz, M. Santacoloma, L. Corredor, and E. Reinosa. 2009. Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia. Antimicrob. Agent Chemother. 53:4022-4024.
5. Andersen, L. P., and T. Wadstrom. 2001. Basic bacteriology and culture, p. 947-961. In H. L. T. Mobley, G. L. Mendz, and S. L. Hazell (ed.), Helicobacter pylori: physiology and genetics. ASM Press, Washington, DC.
6. Atherton, J. C., T. L. Cover, R. J. Twells, M. R. Morales, C. J. Hawkey, and M. J. Blaser. 1999. Simple and accurate PCR-based system for typing vacuolating cytotoxin alleles of Helicobacter pylori. J. Clin. Microbiol. 37:2979-2982.
7. Boyanova, L., R. Markovska, D. Yordanov, M. Marina, K. Ivanova, S. Panayotov, G. Gergova, and I. Mitov. 2009. High prevalence of virulent Helicobacter pylori strains in symptomatic Bulgarian patients. Diagn. Microbiol. Infect. Dis. 6:374-380.
8. Cambau, E., V. Allerheiligen, C. Coulon, C. Corbel, C. Lascols, L. Deforges, C. J. Soussy, J. C. Delchier, and F. Megraud. 2009. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J. Clin. Microbiol. 7:3600-3607.
9. Chey, W. D., and B. C. Wong. 2007. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol. 102:1808-1825.
10. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing: 17th informational supplement. M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
11. De Francesco, V., M. Margiotta, A. Zullo, C. Hassan, F. Giorgi, M. Zotti, G. Stoppiono, A. Bastianello, Diterlizzi, G. Verderosa, S. Morini, C. Panella, and E. Ierardi. 2009. Helicobacter pylori vacA arrangement and related diseases: a retrospective study over a period of 15 years. Dig. Dis. Sci. 54:97-102.
12. De Francesco, V., M. Margiotta, A. Zullo, C. Hassan, N. Valle, O. Burattini, D'Angelo, R. G. Stoppino, U. Cea, F. Giorgio, R. Monno, S. Morini, C. Panella, and E. Ierardi. 2006. Clarithromycin resistance and Helicobacter pylori genotypes in Italy. J. Microbiol. 44:660-664.
13. De Francesco, V., A. Zullo, E. Lerardi, and D. Vaira. 2009. Minimal inhibitory concentration (MIC) values and different point mutations in the 23S rRNA gene for clarithromycin resistance in Helicobacter pylori. Dig. Liver Dis. 41:610-611.
14. Elitsur, Y., Z. Lawrence, H. Rüssmann, and S. Koletzko. 2006. Primary clarithromycin resistance to Helicobacter pylori and therapy failure in children: the experience in West Virginia. J. Pediatr. Gastroenterol. Nutr. 42:327-328.
15. Evans, D. J., and D. G. Evans. 2001. Helicobacter pylori CagA: analysis of sequence diversity in relation to phosphorylation motifs and implications for the role of cagA as a virulence factors. Helicobacter 6:187-198.
16. Fariña, N., E. Kasamatsu, M. Samudio, M. Morán, R. Sanabria, and F. Laspina. 2007. Antimicrobial susceptibility of H pylori strains obtained from Paraguayan patients. Rev. Med. Chil. 135:1009-1014.
17. Fox, J., and F. Megraud. 2007. Helicobacter, p. 947-961. In P. R. Murray, E. J. Baron, M. A. Pfaller, J. H. Jorgensen, and R. H. Yolken (ed.), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
18. Glupczynski, Y. 1996. Culture of Helicobacter pylori from gastric biopsies and antimicrobial susceptibility testing, p. 17-32. In A. Lee and F. Megraud (ed.), Helicobacter pylori: techniques for clinical diagnosis and basic research. W. B. Saunders Company Ltd., Baltimore, MD.
19. Horiki, N., F. Omata, M. Uemura, S. Suzuki, N. Ishii, Y. Iizuka, K. Fukuda, Y. Fujita, M. Katsurahara, T. Ito, G. E. Cesar, I. Imoto, and Y. Takei. 2009. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter 14:86-90.
20. Kim, J. M., J. S. Kim, N. Kim, Y. J. Kim, I. Y. Kim, L. Y. Chee, C. H. Lee, and H. C. Jung. 2008. New mutations of 23S rRNA associated with clarithromycin resistance in Helicobacter pylori strains isolated from Korean patients. J. Microbiol. Biotechnol. 18:1584-1589.
21. Koletzko, S., F. Richy, P. Bontems, J. Crone, N. Kalach, M. L. Monteiro, F. Gottrand, D. Celinska-Cedro, E. Roma-Giannikou, G. Orderda, S. Kolacek, P. Urruzuno, M. J. Martínez-Gómez, T. Casswall, M. Ashorn, H. Bodanszky, and F. Mégraud. 2006. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 55:1711-1716.
22. Liu, Z., P. Zheng, and P. Yang. 2008. Efflux pump gene hefA of Helicobacter pylori plays an important role in multidrug resistance. World J. Gastronterol. 14:5217-5222.
23. López-Brea, M., J. Martínez, D. Domingo, and T. Alarcón. 2001. A 9 year study of clarithromycin and metronidazole resistance in Helicobacter pylori from Spanish children. J. Antimicrob. Chemother. 48:295-297.
24. Malfertheiner, P., F. Megraud, C. O'Morain, F. Bazzoli, E. El-Omar, D. Graham, R. Hunt, T. Rokkas, N. Vakil, and E. Kuipers. 2007. Concepts in the management of Helicobacter pylori infection. The Maastricht III Consensus Report. Gut 56:772-781.
25. Mana, F. 2009. The Maastricht III consensus: summary and comments. Acta Gastroenterol. Belg. 72:344-349.
26. Mégraud, F., and P. Lehours. 2007. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin. Microbiol. Rev. 20:280-322.
27. Megraud, F. 2004. H. pylori antibiotic resistance: prevalence, importance and advantages in testing. Gut 53:1374-1384.
28. O'Connor, A., J. Gisbert, and C. O'Morain. 2009. Treatment of Helicobacter pylori infection. Helicobacter 1:46-51.
29. Panayotopoulou, E., D. Sgouras, K. Papadakos, A. Kalliaropoulos, G. Papatheodoridis, A. Mentis, and A. Archimandritis. 2007. Strategy to characterize the number and type of repeating EPIYA phosphorylation motifs in the carboxyl terminus of CagA protein in Helicobacter pylori clinical isolates. J. Clin. Microbiol. 45:488-495.
30. Perez Aldana, L., M. Kato, S. Nakagawa, M. Kawarasaki, T. Nagasako, T. Mizushima, H. Oda, J. Kodaira, Y. Shimizu, Y. Komatsu, R. Zheng, H. Takeda, T. Sugiyama, and M. Asaka. 2002. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 7:306-309.
31. Rimbara, E., T. Kawai, and M. Sasatsu. 2008. Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. Antimicrob. Agents Chemother. 52:3465-3466.
32. Shanks, A. M., and E. M. El-Omar. 2000. Helicobacter pylori infection, host genetics and gastric cancer J. Dig. Dis. 10:157-164.
33. Sugimoto, M., and Y. Yamaoka. 2009. Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy. Arch. Immunol. Ther. 57:45-56.
34. Taneike, I., A. Nami, A. O'Connor, N. Fitzgerald, P. Murphy, A. Qasim, H. O'Connor, and C. O'Morain. 2009. Analysis of drug resistance and virulence-factor genotype of Irish Helicobacter pylori strains: is there any relationship between resistance to metronidazole and cagA status? Aliment. Pharmacol. Ther. 30:784-790.
35. Tanuma, M., E. Rimbara, N. Noguchi, S. Boonyaritiikij, K. Kuwabara, Y. Fukunaga, and M. Sasatsu. 2009. Analysis of clarithromycin resistance and cagA status in Helicobacter pylori using feces from children in Thailand. J. Clin. Microbiol. 47:4144-4145.
36. Taylor, D. E., Z. Ge, D. Purych, T. Lo, and K. Hiratsuka. 1997. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob. Agents Chemother. 41:2621-2628.
37. Vallejos, C., L. Garrido, D. Cáceres, A. M. Madrid, C. Defilippi, C. Defilippi, and H. Toledo. 2007. Prevalence of metronidazole, clarithromycin and tetracycline resistance in Helicobacter pylori isolated from Chilean patients Rev. Med. Chil. 135:287-293.
38. van Doorn, L. J., P. M. Scheneeberger, N. Nouban, A. P. Plaisier, W. G. V. Quint, and W. A. de Boer. 2000. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut 46:321-326.